Intersect ENT, Inc. (XENT)
(Delayed Data from NSDQ)
$33.65 USD
+1.22 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.66 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.65 USD
+1.22 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.66 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Intersect ENT Rides on Innovation Amid Pricing Concerns
by Zacks Equity Research
The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.
Intersect ENT (XENT) Down 18.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intersect (XENT) Q2 Loss Wider Than Estimates, Revenues Miss
by Zacks Equity Research
Intersect ENT's (XENT) lowered revenue guidance for 2019 raises concern.
Intersect ENT (XENT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -5.88% and -1.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Intersect ENT (XENT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Intersect ENT (XENT) Down 8.3% Since Last Earnings Report?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.
Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 1.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intersect ENT Grows on Product Launch Amid Pricing Pressure
by Zacks Equity Research
Intersect ENT (XENT) recently finishes the ENCORE Study, which is a small 50-patient open label program, designed to evaluate the safety of the repeat use of SINUVA.
Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intersect ENT (XENT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of 3.85% and 2.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT (XENT) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Intersect ENT (XENT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.
Moving Average Crossover Alert: Intersect ENT (XENT)
by Zacks Equity Research
Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective
Intersect ENT (XENT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of 17.65% and -6.29%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT (XENT) SINUVA Implant Receives FDA Approval
by Zacks Equity Research
Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
5 MedTech Stocks for Stellar Returns in Q3
by Zacks Equity Research
Here we take a sneak peek into two burning issues that are likely to impact the quarterly numbers in the MedTech fraternity.
The Saga to Revoke Obamacare Continues: 3 MedTech Picks
by Zacks Equity Research
In the wake of the turbulent political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable picks.
Intersect ENT: FDA Submission of RESOLVE Implant, Stock Up
by Zacks Equity Research
Intersect ENT, Inc (XENT) recently announced the submission of a New Drug Application (NDA) approval with the U.S. FDA for reviewing its investigational RESOLVE steroid releasing implant.